Lentiviral Titers with VirusExpress^®

WEBINAR

Along with its many notable advantages, lentiviral vectors' attractiveness lies in their ability to be used in a wide range of cell and gene therapy indications, beyond rare diseases to serve larger patient populations. Recent regulatory approvals and clinical trial successes have led to a growing pipeline and interest in therapies using lentiviral vectors. And with that, an increased need for a robust, scalable production technology that improves overall yield and quality.

In this webinar, our upstream and downstream innovation scientists will explore how they optimized our VirusExpress^® production technology for lentiviral vectors to maximize titer while providing a streamlined platform to accelerate development timelines to clinical trials.

In this webinar, you will learn how our VirusExpress^® production technology:

• Offers optimized upstream and downstream workflows for lentiviral-based production
• Provides a streamlined, consistent production technology to seamlessly and robustly scale up to commercial manufacturing
• Reduces time to clinical/commercial manufacturing